Alkermes Appoints Joshua Reed as Chief Financial Officer
Alkermes (Nasdaq: ALKS) has appointed Joshua Reed as Chief Financial Officer, effective September 15, 2025. Reed brings over 30 years of financial leadership experience in biotechnology and pharmaceutical sectors, most recently serving as CFO of Omega Therapeutics.
Reed's extensive background includes CFO roles at Aldeyra Therapeutics and leadership positions at Bristol Myers Squibb, where he served as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. He currently serves on the board of Scholar Rock Holding Corporation and holds degrees from Rutgers University and the University of Michigan's Ross School of Business.
Alkermes (Nasdaq: ALKS) ha nominato Joshua Reed come Chief Financial Officer, con effetto dal 15 settembre 2025. Reed porta oltre 30 anni di esperienza nella direzione finanziaria nei settori biotecnologico e farmaceutico, avendo ricoperto recentemente il ruolo di CFO di Omega Therapeutics.
La vasta esperienza di Reed comprende ruoli di CFO in Aldeyra Therapeutics e posizioni di leadership presso Bristol Myers Squibb, dove ha ricoperto il ruolo di Vice President e Capo delle Operazioni Finanziarie per gli Stati Uniti e Porto Rico. Attualmente è nel consiglio di Scholar Rock Holding Corporation e possiede lauree presso la Rutgers University e la Ross School of Business dell'Università del Michigan.
Alkermes (Nasdaq: ALKS) ha designado a Joshua Reed como Chief Financial Officer, con efecto a partir del 15 de septiembre de 2025. Reed aporta más de 30 años de experiencia en liderazgo financiero en los sectores de biotecnología y farmacéutica, habiendo ocupado recientemente el cargo de CFO de Omega Therapeutics.
La amplia trayectoria de Reed incluye cargos de CFO en Aldeyra Therapeutics y puestos de liderazgo en Bristol Myers Squibb, donde se desempeñó como Vicepresidente y Jefe de Operaciones Financieras para Estados Unidos y Puerto Rico. Actualmente forma parte de la junta directiva de Scholar Rock Holding Corporation y posee titulaciones de Rutgers University y de la Ross School of Business de la University of Michigan.
Alkermes (Nasdaq: ALKS)가 Joshua Reed를 최고재무책임자(CFO)로 임명했으며 발효일은 2025년 9월 15일입니다. Reed는 생명공학 및 제약 부문에서 30년이 넘는 재무 리더십 경험을 보유하고 있으며, 최근 Omega Therapeutics의 CFO를 역임했습니다.
Reed의 폭넓은 경력에는 Aldeyra Therapeutics의 CFO 직무와 Bristol Myers Squibb에서 미국 및 푸에르토리코의 재무 운영 책임 부사장으로의 리더십이 포함됩니다. 현재 Scholar Rock Holding Corporation 이사회에 재직 중이며 Rutgers University와 University of Michigan의 Ross School of Business에서 학위를 보유하고 있습니다.
Alkermes ( Nasdaq : ALKS ) a nommé Joshua Reed au poste de directeur financier, à compter du 15 septembre 2025. Reed apporte plus de 30 ans d'expérience en leadership financier dans les secteurs de la biotechnologie et des produits pharmaceutiques, ayant récemment occupé le poste de CFO chez Omega Therapeutics.
Le parcours de Reed comprend des rôles de CFO chez Aldeyra Therapeutics et des postes de direction chez Bristol Myers Squibb, où il a été Vice-président et Responsable des opérations financières pour les États‑Unis et Porto Rico. Il siège actuellement au conseil d'administration de Scholar Rock Holding Corporation et est diplômé de Rutgers University et de la Ross School of Business de l'Université du Michigan.
Alkermes (Nasdaq: ALKS) hat Joshua Reed zum Chief Financial Officer ernannt, wirksam zum 15. September 2025. Reed bringt über 30 Jahre Erfahrung in der Finanzführung in den Biotechnologie- und Pharmasektoren mit und war zuletzt CFO von Omega Therapeutics.
Reeds umfassender Hintergrund umfasst CFO-Rollen bei Aldeyra Therapeutics und Führungspositionen bei Bristol Myers Squibb, wo er als Vice President und Head of Finance Operations für die USA und Puerto Rico tätig war. Er ist derzeit im Vorstand der Scholar Rock Holding Corporation und besitzt Abschlüsse der Rutgers University und der Ross School of Business der University of Michigan.
Alkermes (ناسداك: ALKS) عيّنت جاوشوا ريد كـرئيس مالي تنفيذي، اعتباراً من 15 سبتمبر 2025. يجلب ريد أكثر من 30 عاماً من خبرة القيادة المالية في قطاعات التكنولوجيا الحيوية والأدوية، وكان آخر عمل له كـCFO في Omega Therapeutics.
تشمل خلفيته الواسعة أدوار CFO في Aldeyra Therapeutics ومناصب قيادية في Bristol Myers Squibb، حيث شغل منصب نائب الرئيس ورئيس عمليات التمويل في الولايات المتحدة وبورتو ريكو. وهو حالياً عضو في مجلس إدارة Scholar Rock Holding Corporation ويحمل درجات من Rutgers University وRoss School of Business بجامعة ميشيغان.
Alkermes (纳斯达克股票代码：ALKS) 已任命 Joshua Reed 为首席财务官，任期自 2025 年 9 月 15 日生效。Reed 拥有超过 30 年的金融领导经验，在生物技术与制药行业，最近担任 Omega Therapeutics 的首席财务官。
Reed 的丰富背景还包括在 Aldeyra Therapeutics 担任 CFO，以及在 Bristol Myers Squibb 担任领导职位，曾任美国与波多黎各的金融运营部副总裁兼负责人。现任 Scholar Rock Holding Corporation 董事会成员，并拥有 Rutgers University 与密歇根大学罗斯商学院的学位。
- Appointment of seasoned CFO with over 30 years of financial leadership experience
- Strong industry expertise from major companies including Bristol Myers Squibb
- Additional strategic insight from current board position at Scholar Rock
- None.
"I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.
Mr. Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics, a then publicly-traded biotechnology company. Prior to that, he was the CFO at Aldeyra Therapeutics. Earlier in his career, Mr. Reed spent more than a decade at Bristol Myers Squibb, culminating in his role as Vice President and Head of Finance Operations for the
Mr. Reed currently serves on the board of directors of Scholar Rock Holding Corporation, a publicly-traded biotechnology company. He earned a Bachelor of Science in Finance from Rutgers University and a Master of Business Administration from the University of
"We are pleased to welcome Joshua to Alkermes at such an exciting time in our company's evolution," said Mr. Pops. "Joshua brings a wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry. We gain his financial acumen and dedication to excellence as we continue to focus on driving strong performance across our commercial business, advancing our pipeline, and delivering long-term shareholder value. I look forward to the positive impact he will have across our organization."
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contacts: | |||
For Investors: | Sandy Coombs | +1 781 609 6377 | |
For Media: | Katie Joyce | +1 781 249 8927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-appoints-joshua-reed-as-chief-financial-officer-302554407.html
SOURCE Alkermes plc
FAQ
Who is the new CFO of Alkermes (ALKS)?
What is Joshua Reed's previous experience before joining Alkermes?
What are Alkermes' (ALKS) main business areas?
When does Joshua Reed start as Alkermes CFO?
